Staff at the Office of Technology Development can help you learn about technologies available for licensing and opportunities for new collaborations with Memorial Sloan-Kettering scientists.
Memorial Sloan-Kettering Cancer Center's Office of Technology Development (OTD) is responsible for managing the discoveries of Memorial Sloan-Kettering Cancer Center investigators. We evaluate, protect, market, and license new inventions, and negotiate agreements for sponsored research, clinical trials, and material transfer.
Memorial Sloan-Kettering Cancer Center researchers pursue basic and clinical research to advance the ability to prevent, control, and cure cancer. Ongoing research at the Sloan-Kettering Institute, the basic research arm of Memorial Sloan-Kettering Cancer Center, is yielding new insights into the biology of cancer. Memorial Sloan-Kettering Cancer Center scientists are engaged in research in such diverse areas as cell signaling, developmental biology, tumor immunology, immunotherapy, transplantation biology, human cancer genetics, drug development, and clinical therapeutics.
The other development arm of Memorial Sloan-Kettering Cancer Center, the clinical sector, carries out clinical trials and retrospective studies in all areas of cancer research, both investigator-initiated and industry-initiated projects. While most research revolves around cancer, Memorial Sloan-Kettering Cancer Center scientists are also developing new therapies for immune system disorders, infectious diseases, and drug addiction. Memorial Sloan-Kettering Cancer Center is committed to developing affordable technologies for use worldwide; thus the OTD considers both the social and financial benefits of new opportunities.
One of Memorial Sloan-Kettering Cancer Center's greatest strengths is the close collaboration between laboratory and clinical investigators, thereby facilitating the translation of research from the laboratory to the bedside. Memorial Sloan-Kettering Cancer Center conducts one of the most comprehensive clinical investigation programs in the world, which includes studies to evaluate the efficacy of standard cancer therapies and test new approaches to preventing, diagnosing, and treating cancer.
If you are interested in learning more about the technologies available for licensing at Memorial Sloan-Kettering Cancer Center, please contact Sharon R. Seiler, PhD, OTD’s Senior Manager, Technology Management and Commercialization (seilers@mskcc.org), or any other members of our staff, who can inform you of developing collaborations with scientists.
For MSKCC Investigators
View the Office of Technology Development's Intranet page.
